Liquidia price target raised to $55 from $45 at Jefferies

Jefferies analyst Amy Li raised the firm’s price target on Liquidia (LQDA) to $55 from $45 and keeps a Buy rating on the shares after the company announced “strong” preliminary Q4 Yutrepia sales of $90.1M, which beat consensus expectations by about 22%, and announced plans to initiate and support several expansion studies. Following the update, the firm is increasing its Yutrepia sales estimates and expects the launch to beat consensus under “conservative patient-add assumptions.”